Vitruvian Partners
Private equity firm backing higher-growth companies across Europe and the US.
Available information varies by company and source.
Profile record updated:
Company facts
- Official name
- Vitruvian Partners LLP
- Entity type
- COMPANY
- Founded
- 2006
- Headquarters
- 105 Wigmore Street, London, W1U 1QY
- Company size
- 50–200
- Official website
- vitruvianpartners.com
What Vitruvian Partners does
Vitruvian Partners operates a fund-management model. It raises committed capital from limited partners into private equity funds, sources and executes investments in growth-stage and buyout opportunities, supports portfolio value creation, and monetises through recurring management fees on assets under management plus carried interest on realised investment gains.
Category differentiation
Vitruvian Partners is a private equity and growth capital investor, not an adtech, martech or software vendor. It manages investment funds rather than selling enterprise software or media inventory.
Strategic context
AI-supported assessment from the existing company research; distinguish interpretation from sourced facts.
Vitruvian Partners LLP is a private equity investment firm headquartered in London. It raises capital into investment funds and deploys that capital into ambitious higher-growth companies through growth equity and buyout transactions. The firm serves institutional investors and other capital providers on the fund side, while backing portfolio companies with capital and strategic support on the operating side. The firm generates revenue primarily from fund management fees and performance-linked carried interest. The supplied evidence shows a multi-office footprint across London, Munich, Stockholm, Luxembourg and San Francisco, and the latest financial evidence states that Vitruvian funds have backed over 100 companies and have assets under management of approximately €20 billion.
Company news briefing
Briefing updated:
Vitruvian Partners has continued to expand its healthcare and adtech portfolio through major investments, led by a $637 million majority stake in DeepIntent—which recently launched its AI-powered agentic advertising platform, Cora, for pharmaceutical marketers. Additionally, Vitruvian led a $600 million funding round in health insurance startup Angle Health at a $2.7 billion valuation. These developments highlight Vitruvian's ongoing backing of technology-driven platforms navigating complex regulatory and digital environments.
Business model & monetisation
The firm monetises through private equity fund economics: recurring management fees charged on committed or managed capital, and carried interest earned as a share of profits on successful exits. Commercial value is created by fundraising, disciplined capital deployment, portfolio growth, and realisation events such as acquisitions or IPOs.
- Fund management fees
- Recurring fees on assets under management or committed capital
- Carried interest
- Performance-based share of realised investment profits
- Co-investment and related fund economics
- Investment-related participation alongside core funds
Products & capabilities
No products with linked sources are available in this view.
Subsidiaries & acquisitions
- DeepIntent
Healthcare-focused DSP and marketing cloud for pharmaceutical advertising.
Recent recorded signals
Dates refer to the source publication. Older entries are historical context, not evidence of a new event.
Angle Health raises $600M at $2.7B valuation
Funding · Recorded impact score: 2/5
Health insurance startup Angle Health announced a $200 million Series C round and a $400 million tender offer, giving the company a $2.7 billion valuation. The round was led by Vitruvian Partners with participation from Town Hall Ventures, Blumberg Capital, Portage Ventures, PruVen Capital, and Y Combinator. The tender offer permits employees to cash out shares, and the transaction is expected to close later this month. Angle Health, a Winter 2020 Y Combinator alum, helps small businesses manage level-funded health plans, offering a middle ground between fully insured and self-funded options. The company's AI-powered platform integrates with payroll and HR systems, serves over 5,000 businesses, and is reportedly profitable. This funding round is notable as it comes from a non-AI-agent startup founded in 2019.
- Angle Health raised a $200 million Series C round.
- The funding round included a $400 million tender offer.
DeepIntent launches agentic ad platform Cora for pharma marketing
Agentic Advertising · Recorded impact score: 4/5
DeepIntent, a healthcare-focused adtech firm, has launched Cora, an AI-powered agentic advertising platform designed for pharmaceutical marketers. The platform uses multiple AI agents to handle campaign planning, audience strategy, and media execution, including linear TV via a VideoAmp integration. Cora aims to speed up marketing workflows, with beta tests showing a 50% reduction in planning cycles and over 95% of clients reporting faster processes. This launch follows DeepIntent's majority stake sale to Vitruvian Partners, which provided $637 million to develop AI tools. The company targets the growing complexity of pharma marketing, especially for niche drugs targeting small patient populations. Cora is also powered by Helix, a data application providing aggregated healthcare data, including payer signals and drug coverage insights.
- DeepIntent launched Cora, an agentic ad platform for pharma marketing.
- Cora uses AI agents for campaign planning, audience targeting, and execution.
Explore company relationships
Questions about Vitruvian Partners
What is Vitruvian Partners?
Vitruvian Partners is a London-headquartered private equity firm that invests growth capital and buyout funding into higher-growth companies.
Who uses Vitruvian Partners?
Its direct customers are institutional investors and other limited partners that commit capital to its funds, while portfolio companies use the firm as a funding and strategic partner.
How does Vitruvian Partners make money?
It earns recurring management fees on funds and carried interest from profitable exits on portfolio investments.
Sources & coverage
This profile uses public, official and technically observable information. Missing information does not prove that a product or relationship does not exist. The list below does not imply that every profile statement has been verified.
19 publicly documented primary sources and citations linked across the market graph.
Continue your research on Vitruvian Partners
Explorer includes additional company details, a Watchlist for up to 25 companies and your personal Strategic Intelligence Agent. It monitors your market daily and delivers tailored briefings with clear strategic context whenever relevant news occurs.
Free, with no time limit.